Parmodia tablets 0.1 mg from Japan (hyperlipidemia, dyslipidaemia)
What are Parmodia tablets 0.1 mg for hyperlipidemia?
An active principle of Parmodia is pemafibrate, a peroxisome proliferator-activated receptor alpha agonist. It works by binding to nuclear receptors and regulating the expression of targeted genes. This novel medicine was approved in Japan in 2017. Parmodia tablets are effective for the treatment of hyperlipidemia, including familial hyperlipidemia, and improving atherogenic dyslipidemia. They also lower blood triglyceride levels, cholesterol levels and apolipoprotein levels.
Active principles: pemafibrate
Amount: 100 tablets
Maker: Kowa Co., Ltd., Nagoya, Japan
- improving atherogenic dyslipidemia,
- treating hyperlipidemia (including familial hyperlipidemia),
- reducing remnant cholesterol and increasing HDL cholesterol ("good") cholesterol,
- lowering blood triglyceride levels,
- reducing apolipoprotein CIII,
- increasing serum fibroblast growth factor 21.
How to take
Adults should take 1 tablet (0.1 mg of the active principle) at a time, 2 times a day, in the morning and in the evening. Your doctor may adjust the dosage according to the age or symptoms. The maximum dose of 2 tablets (0.2 mg) at a time, 2 times a day, should not be exceeded.
Contraindications: do not use for the following patients:
- pregnant, possibly pregnant or breastfeeding women,
- patients with liver disorder,
- patients with hepatic cirrhosis,
- patients with biliary atresia or cholelithiasis.
If an allergic reaction occurs, patient needs to stop using the medicine and consult with their doctor. If patient is taking any other medication or treatment, they should consult with their doctor in advance.